GENETIC POLYMORPHISM OF INFLAMMATORY FACTORS IS ASSOCIATED WITH THROMBOEMBOLIC COMPLICATIONS OF ATRIAL FIBRILLATION

Aim. To reveal the association of hereditary specifics of inflammatory factors with the adverse risk in atrial fibrillation (AF).

Material and methods. Totally 258 patients studied (68,5±0,67 y. o.) with nonvalvular AF, recording the events as ischemic stroke, myocardial infarction, venous and arterial thromboembolism. Mean follow-up was 455±11,71 days.

Results. Factors that are independently associated with ischemic stroke development in patients not receiving anticoagulants (n=101), were the allele C of polymorphic marker rs2228145(А/С) of gene IL-6 receptor (OR 13,25 CI 1,57112,18, р=0,018), age ?75 y. o. (OR 1,1, CI 1,008-1,2, р=0,032) and EF LV (OR 0,97 CI 0,94-0,99 р=0,027), with a “thrombotic endpoint” development — DM (OR 4,3 CI 1,46-12,45 р=0,008), EF LV (OR 0,96 CI 0,94-0,98, р<0,0001) and carriage of allele C of polymorphic marker rs2228145(А/С) of receptor to IL-6 gene (OR 4,03 CI 1,0715,26, р=0,04). There was no association with adverse outcomes in genes IL-6 polymorphisms as (G(-174)C and G(-572)C), ИЛ-10 (C(-819)T), ФНО (G(-238)A, G(-308)A and ФНО? rs180630). In those receiving adequate anticoagulant therapy (n=157) there was no significant association of IL-6 receptor gene polymorphism with adverse outcomes.

Conclusion. Therefore, the carriage of allele C of polymorphic marker rs2228145(А/С) of the IL-6 receptor gene might be an independent risk marker for adverse outcome in non-valvular AF, potentially, being a selection tool for those patients not having enough high risk according to common scores. 

1. Zotova I, Zateyschikov D, Sidorenko B. Predictors of intracardiac thrombosis in patients with atrial fibrillation: factors of hemostasis, markers of inflammation and genetic factors. Cardiology 2007, 47(11): 46-54.Russian (Зотова И, Затейщиков Д, Сидоренко Б. Предикторы внутрисердечного тромбоза у больных с мерцательной аритмией: факторы гемостаза, маркеры воспалений и генетические факторы. Кардиология 2007, 47(11): 46-54).

2. Ederhy S, Di Angelantonio E, Dufaitre G, et al. C-reactive protein and transesophageal echocardiographic markers of thromboembolism in patients with atrial fibrillation. International journal of cardiology 2012, 159(1): 40-6.

3. Pinto A, Tuttolomondo A, Casuccio A, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009, 116(10): 781-9.

4. Roldan V, Marin F, Martinez JG, et al. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. Am J Cardiol 2005, 95(7): 881-2.

5. Beckers MM, Ruven HJ, Haas FJ, et al. Single nucleotide polymorphisms in inflammationrelated genes are associated with venous thromboembolism. Eur J Intern Med 2010, 21(4): 289-92.

6. Zee RY, Glynn RJ, Cheng S, et al. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women’s Genome Health Study. Circ Cardiovasc Genet 2009, 2(1): 57-62.

7. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012, 44(12): 1336-40.

8. Ferreira MA, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 2011, 378(9795): 1006-14.

9. Ibrahim I, McAllister K, Plant D, et al. Investigation of an interleukin-6 receptor gene polymorphism (rs2228145) as a predictor of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2014, 73(4): 787-8.

10. Harrison SC, Smith AJ, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J 2013, 34(48): 3707-16.

11. Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 2012, 379(9822): 1205-13.

12. Chen Z, Qian Q, Tang C, et al. Association of two variants in the interleukin-6 receptor gene and premature coronary heart disease in a Chinese Han population. Mol Biol Rep 2013, 40(2): 1021-6.

13. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene, plasma C-reactive protein, and diabetes risk in women. Diabetes 2009, 58(1): 275-278.

14. Stephens OW, Zhang Q, Qu P, et al. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012, 119(2): 503-12.

15. Garbers C, Monhasery N, Aparicio-Siegmund S, et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim Biophys Acta 2014, 1842(9): 1485-94.

16. Abeywardena MY, Leifert WR, Warnes KE, et al. Cardiovascular biology of interleukin-6. Curr Pharm Des 2009, 15(15): 1809-21.

17. Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost 2009, 102(2): 215-22.

18. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6. Int J Biol Sci 2012, 8(9): 1237-47.

19. Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet 2007, 80(4): 716-26.

20. van Dongen J, Jansen R, Smit D, et al. The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav Genet 2014, 44(4): 368-82.